Movement Alert｜Bristol-Myers Squibb Rises 3.13% in Regular Trading, Driven by Analyst Upgrade and Sector Strength

Market Focus06-04 22:36

On June 4, Bristol-Myers Squibb rose 3.13% in regular trading, trading at $56.14/share, with trading volume of $162 million. The rally was supported by multiple positive catalysts including an analyst upgrade and broad pharmaceutical sector strength.

Jefferies raised its price target on Bristol-Myers Squibb from $70 to $73, maintaining a Buy rating. The average analyst rating stands at overweight with a mean price target of $63.26 according to FactSet. The upgrade follows the company's recent positive Phase 3 SUCCESSOR-2 trial results for mezigdomide, which demonstrated a 52% reduction in disease progression or death risk in relapsed or refractory multiple myeloma patients, with median progression-free survival reaching 18 months versus 8.3 months for the control group. Additionally, the European Commission recently approved Opdivo in combination with AVD chemotherapy for previously untreated advanced classical Hodgkin lymphoma, marking the first immunotherapy regimen approved in the EU for this indication.

Within the Pharmacy sector, broad strength provided further support. Among peers, Eli Lilly rose 4.56%, Novo Nordisk rose 4.55%, Merck rose 3.69%, Johnson & Johnson rose 2.02%, and Pfizer rose 1.68%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment